{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:24:53Z","timestamp":1769833493019,"version":"3.49.0"},"reference-count":20,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Anaplastic lymphoma kinase (ALK)- negative anaplastic large cell lymphoma (ALCL) is an aggressive CD30-positive non- Hodgkin lymphoma. ALK-ALCL rarely manifests with extensive bone marrow and peripheral blood involvement (known as \u201cleukemic phase\u201d). A 54-year-old woman was diagnosed with ALK-ALCL in leukemic phase, characterized by an extremely poor prognosis. Lymphoma cells in this case showed chromosomal translocation 1p36.1- encoded RUNX3 and overexpression of its protein. She was refractory to CHOP and salvage chemotherapy. Fortunately, she achieved complete remission with three cycles of Brentuximab vedotin (BV) and underwent umbilical cord blood transplantation. However, she died due to treatment-related mortality on day 129. The autopsy findings showed no lymphoma cells. Treatment strategy for ALK-ALCL is controversial, but the efficacy of BV in CD30-positive peripheral T-cell lymphoma not only as salvage regimens, but also in first line, has been reported in recent years. BV may be an effective option for ALK-ALCL in leukemic phase.<\/jats:p>","DOI":"10.4081\/hr.2020.8368","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T14:58:29Z","timestamp":1589554709000},"page":"8368","source":"Crossref","is-referenced-by-count":4,"title":["Brentuximab Vedotin for Refractory Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma in Leukemic Phase with RUNX3 Overexpression"],"prefix":"10.3390","volume":"12","author":[{"given":"Yusuke","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Kosako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Oiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Warigaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Mushino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinori","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Sonoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinobu","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.critrevonc.2012.06.004","article-title":"Anaplastic large cell lymphoma, ALKnegative","volume":"85","author":"Ferreri","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.leukres.2009.07.034","article-title":"ALKnegative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as \u201cleukemic phase\u201d","volume":"34","author":"Lu","year":"2010","journal-title":"Leuk Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1038\/leu.2017.40","article-title":"RUNX3 is oncogenic in natural killer\/Tcell lymphoma and is transcriptionally regulated by MYC","volume":"31","author":"Selvarajan","year":"2017","journal-title":"Leukemia"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000454890","article-title":"High-Dose Methotrexate and Cytarabine- Based Multi-Agent Chemotherapy (Modified Bonn Protocol) for Systemic Lymphoma with CNS Involvement","volume":"137","author":"Umino","year":"2017","journal-title":"Acta Haematol"},{"key":"ref7","first-page":"2993","article-title":"Prognostic significance of CD 56 expression for ALK-positive and ALKnegative anaplastic large-cell lymphoma of T\/null cell phenotype","volume":"96","author":"Suzuki","year":"2000","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e0191461","DOI":"10.1371\/journal.pone.0191461","article-title":"The risk of central nervous system relapses in patients with peripheral T-cell lymphoma","volume":"13","author":"Chihara","year":"2018","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood-2014-12-616961","article-title":"Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study","volume":"126","author":"Ellin","year":"2015","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.3109\/10428194.2010.502585","article-title":"ALKnegative anaplastic large cell lymphoma in leukemic phase with near- pentaploidy","volume":"51","author":"Wong","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00277-010-1074-2","article-title":"Adult anaplastic large cell lymphoma involving the central nervous system: a rare clinical scenario","volume":"90","author":"Zhang","year":"2011","journal-title":"Ann Hematol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.bbmt.2006.08.035","article-title":"Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non- Hodgkin\u2019s lymphoma","volume":"12","author":"Rodriguez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref16","first-page":"2596423","article-title":"Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature","volume":"2016","author":"Delacruz","year":"2016","journal-title":"Case Rep Oncol Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11899-018-0432-3","article-title":"The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL)","volume":"13","author":"Ma","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1365-2567.2010.03381.x","article-title":"Interplay of transcription factors in T-cell differentiation and function: the role of Runx","volume":"132","author":"Wong","year":"2011","journal-title":"Immunology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.leukres.2015.09.009","article-title":"FLT3-ITD drives Ara-C resistance in leukemic cells via the induction of RUNX3","volume":"39","author":"Damdinsuren","year":"2015","journal-title":"Leuk Res"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.pagepress.org\/journals\/index.php\/hr\/article\/download\/8368\/8253","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.pagepress.org\/journals\/index.php\/hr\/article\/download\/8368\/8256","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mdpi.com\/2038-8330\/12\/1\/8368\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T07:24:38Z","timestamp":1645601078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/12\/1\/8368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["hr.2020.8368"],"URL":"https:\/\/doi.org\/10.4081\/hr.2020.8368","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,15]]}}}